- WKN: 661472
- ISIN: DE0006614720
- Land: Deutschland
Nachricht vom 25.05.2012 | 23:51
WILEX AG reports on Annual General Meeting 2012
WILEX AG / Key word(s): AGM/EGM
WILEX reports on Annual General Meeting 2012
- Dr Birgit Kudlek elected as new member of the Supervisory Board
- FDA confirms Advisory Committee meeting
Munich, Germany, 25 May 2012. WILEX AG (ISIN DE0006614720 / WL6 / FWB) today announced that the Company's ordinary Annual General Meeting has elected Dr Birgit Kudlek as a new member of the Supervisory Board. Dr Kudlek succeeds Dr Alexandra Goll, who stepped down from the Supervisory Board effective December 2011.
'We are pleased to have Dr Kudlek as a further member of the Supervisory Board with excellent industry knowledge and experience in the development and manufacturing of pharmaceutical products' commented Professor Christof Hettich, Chairman of WILEX AG's Supervisory Board.
The shareholders of WILEX AG approved all management proposals put to vote at the meeting with a large majority including:
- Formal approval of the activities of the members of the Executive Management Board and the members of the Supervisory Board
- Election of Deloitte & Touche GmbH Wirtschaftsprüfungsgesellschaft to serve as the auditor of the annual financial statements for the 2011/2012 financial year
- Resolution to revoke the existing Authorised Capital 2010/II and create new Authorised Capital 2012/I as well as to amend the Articles of Association correspondingly
At the Annual General Meeting of WILEX AG 73.34% of the voting shares were represented.
At the meeting WILEX presented the current status of the clinical trials. The Company had previously informed its shareholders that the FDA proposed using an Advisory Committee to review the development strategy for REDECTANE(R). The FDA has now confirmed that the Oncologic Drugs Advisory Committee (ODAC), scheduled for the 25th July 2012, will be the forum for this discussion. The ODAC will be asked to discuss and provide general advice on the extent to which, if any, the pre-surgical identification of clear cell carcinoma of the kidney using an imaging test provides useful clinical information.
All information regarding the Annual General Meeting is published on the Company's website: http://www.wilex.de/press-investors/annual-general-meeting/agm2012/
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will', 'should', 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
End of Corporate News
25.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
|Phone:||+49 (0)89 41 31 38 - 0|
|Fax:||+49 (0)89 41 31 38 - 99|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart|
|End of News||DGAP News-Service|
Anleihe im Fokus
7,75% p.a. - Rendite aus Familienhand
– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs
Syzygy AG: Aktie kaufen
Die nach den ersten drei Monaten des laufenden Jahres von Syzygy präsentierten Zahlen liegen im Rahmen unserer Erwartungen. Angesichts unserer unveränderten Prognosen behalten wir das bisherige Kursziel von 5 € bei und erneuern das Rating KAUFEN.
Der AKTIONÄR News
21. Mai 19:25 400-Prozent-Aktie: Spekulationen um Apple
21. Mai 15:17 Commerzbank: Staatsbeteiligung sinkt drastisch
Analysts' conference call on 1Q 2013
15. Mai 2013
Original-Research: Orad Hi Tec Systems (von VEM Aktienbank AG): Kaufen
21. Mai 2013